Discovery of 177Lu-PSMA-MN4 as an improved PSMA-targeted radioligand with enhanced antitumor efficacy.

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42810190

Chenchen Cai; Chunmiao Qu; Kai Lv; Manchao Song; Mingjie Zhang; Peishang Li; Sheng Zhou; Xiangsheng Kong; Xue Wang; Yuechen Li; Zhiqian Wang

Sep 30, 2026